May 7, 2019
Targeting bile duct cancer – meet Mitesh Borad, M.D.
By Sharon Rosen
The search for treatment targets for patients with bile duct cancer, also known as cholangiocarcinoma, has taken a 360 degree turn, offering new hope for patients. That’s according to Mitesh Borad, M.D., deputy director for Center for Individualized Medicine Biomarker Discovery Program at Mayo Clinic’s Arizona campus, Dr. Borad and his colleagues are using new […]
Tags: #Dr. Mitesh Borad, #liver cancer, #targeted therapies, bile duct cancer, Biomarker Discovery Program, cholangiocarcinoma, fibroblast growth factor receptor (FGFR) inhibitors, Genetic Testing, genomics, Liquid biopsy, mayo clinic, Mayo Clinic Center for Individualized Medicine